Electrical Muscle Stimulation for Breathing and Leg Muscle Weakness in COPD
Tests electrical muscle stimulation on breathing and leg muscles in people with COPD.
Plain-language title generated from the registry record
Registry title: Multimodal Assessment of NMES Effects on Respiratory and Peripheral Muscles in COPD
Key facts
- Where
- Bandung, IndonesiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT07910006, who can take part
Where in Indonesia
- Faculty of Medicine Universitas PadjadjaranBandung, IndonesiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitas Padjadjaran
- Trial code
- NCT07910006
- Record updated
- 2 November 2026
- Original description
The goal of this clinical trial is to learn if targeted neuromuscular electrical stimulation (NMES) can treat respiratory and peripheral muscle weakness in patients with chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are:Read full original descriptionShow less
COMPARATIVE EFFECTS OF TARGETED NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) ON RESPIRATORY AND PERIPHERAL MUSCLES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): A MULTIMODAL ASSESSEMENT USING DIAPHRAGM ULTRASOUND AND PLASMA BIOMARKERS (IL-6 AND IGF-1)
The goal of this clinical trial is to learn if targeted neuromuscular electrical stimulation (NMES) can treat respiratory and peripheral muscle weakness in patients with chronic obstructive pulmonary disease (COPD). The main questions it aims to answer are:
* Does targeted NMES improve diaphragm thickening fraction and excursion as measured by diaphragm ultrasound? * What are the comparative effects of targeted NMES on plasma biomarkers, specifically Interleukin-6 (IL-6) and Insulin-like Growth Factor-1 (IGF-1)? Researchers will compare three groups: the first intervention group receiving intercostal NMES combined with Pursed-Lip Breathing (PLB), the second intervention group receiving quadriceps NMES combined with PLB, and a control group receiving sham upper trapezius NMES combined with PLB, to see if targeted NMES provides superior improvements in respiratory and peripheral muscle function.
Participants will:
* Undergo baseline screening, including a diaphragm ultrasound and a blood draw for plasma biomarkers (IL-6 and IGF-1) * Be randomly assigned to one of the three groups to receive either intercostal NMES, quadriceps NMES, or sham upper trapezius NMES, all combined with Pursed-Lip Breathing exercises * Complete a post-intervention assessment involving repeat ultrasound imaging and biomarker analysis to evaluate muscle and systemic changes
Inclusion: Patients diagnosed with stable Chronic Obstructive Pulmonary Disease (COPD), GOLD spirometric grade 2-4 (post-bronchodilator FEV1/FVC <0.70 with FEV1 <80% predicted), confirmed by a pulmonologist; Age between 40 and 85 years old; Willing to participate in the study and sign the written informed consent form.
Exclusion: Current use of systemic (oral) corticosteroids or history of use within 4 weeks prior to enrollment; Recent thoracic or abdominal surgery, pneumothorax, or a history of spontaneous pneumothorax; Presence of neuromuscular, bulbar, laryngeal, or other disorders that may independently impair respiratory muscle function; Use of a cardiac pacemaker or any metal/electronic implant at the intended stimulation area; Diagnosis of heart failure classified as NYHA (New York Heart Association) class III-IV; Participation in other structured respiratory muscle training or pulmonary rehabilitation programs that may confound the study results; Presence of skin lesions, open wounds, or active dermatitis in the intended electrode placement areas.